title: Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract.
abstract: OBJECTIVE
  The purpose of this trial was to evaluate an immunoassay for urinary nuclear matrix protein, NMP22, as an indicator for transitional cell carcinoma of the urinary tract.
  
  
  METHODS
  Three groups of subjects participated in this trial of NMP22: 1-175 with transitional cell carcinoma, 2-117 with benign urinary tract conditions and 3-375 healthy volunteers. Each subject provided a single (3 voids) urine sample for analysis at the time of study entry. Each sample was assayed for the level of NMP22.
  
  
  RESULTS
  In normal healthy volunteers and in subjects with benign conditions median NMP22 levels were 2.9 and 3.3 units per ml., respectively. Median urinary NMP22 levels in patients with transitional cell carcinoma were significantly greater than in comparison subjects. Patients with active transitional cell carcinoma had significantly greater median urinary NMP22 levels than those with no evidence of disease (6.04 versus 4.11 units per ml., p = 0.027, 1-tailed Mann-Whitney U test). We noted no effect of tumor grade, extent of disease or exposure to intravesical therapy on urinary NMP22 levels.
  
  
  CONCLUSIONS
  NMP22 is a promising urinary tumor marker for monitoring transitional cell carcinoma. Nuclear matrix proteins are a new class of tumor markers that represent the basis for the development of assays with increased efficacy for the detection and treatment of cancer.
authors.affiliation: Boston City Hospital, Massachusetts, USA.
authors.forename: G A
authors.initials: GA
authors.lastname: Carpinito
authors.forename: W M
authors.initials: WM
authors.lastname: Stadler
authors.forename: J V
authors.initials: JV
authors.lastname: Briggman
authors.forename: G W
authors.initials: GW
authors.lastname: Chodak
authors.forename: P A
authors.initials: PA
authors.lastname: Church
authors.forename: D L
authors.initials: DL
authors.lastname: Lamm
authors.forename: P H
authors.initials: PH
authors.lastname: Lange
authors.forename: E M
authors.initials: EM
authors.lastname: Messing
authors.forename: R M
authors.initials: RM
authors.lastname: Pasciak
authors.forename: G B
authors.initials: GB
authors.lastname: Reservitz
authors.forename: R N
authors.initials: RN
authors.lastname: Ross
authors.forename: D B
authors.initials: DB
authors.lastname: Rukstalis
authors.forename: M F
authors.initials: MF
authors.lastname: Sarosdy
authors.forename: M S
authors.initials: MS
authors.lastname: Soloway
authors.forename: R P
authors.initials: RP
authors.lastname: Thiel
authors.forename: N
authors.initials: N
authors.lastname: Vogelzang
authors.forename: C L
authors.initials: CL
authors.lastname: Hayden
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000652:urine*; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000628:therapy / Q000652:urine*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000652:urine*; D011446:Prospective Studies; D014571:Urologic Neoplasms / Q000473:pathology / Q000628:therapy / Q000652:urine*
chemical_list: D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; C100379:nuclear matrix protein 22